Axsome Therapeutics price target raised to $86 from $80 at Mizuho

Mizuho analyst Graig Suvannavejh raised the firm’s price target on Axsome Therapeutics to $86 from $80 and keeps a Buy rating on the shares. The analyst moving up assumptions around the timing of when the company will file a supplemental new drug application for lead asset AXS-05 in the setting of Alzheimer’s disease agitation and increased the probability of success for AXS-05 in this setting to 75% from 65%. The move is based on positive feedback from a key opinion leader who has prior experience working with the FDA, the analyst tells investors in a research note.